GACVS - Topics
Section navigation
Section navigation
- Adjuvants
- AEFI
- BCG vaccines
- Bell's Palsy following intranasal vaccination
- COVID-19 vaccines
- Dengue vaccines
- Diphtheria, tetanus and pertussis vaccines
- Ebola virus vaccines
- GACVS operations
- Global Vaccine Safety Blueprint
- Hepatitis A
- Hepatitis B vaccines
- Hepatitis E vaccines
- Hexavalent vaccines
- Human papillomavirus vaccines
- Immune overload
- Influenza vaccines
- Japanese encephalitis vaccines
- Malaria vaccines
- Measles vaccines
- Menactra meningococcal vaccine and Guillain-Barré Syndrome
- Meningococcal conjugate vaccine
- MMR vaccines and autism
- Mumps vaccines
- Pentavalent vaccine
- Pharmacovigilance
- Pneumococcal vaccines
- Poliovirus vaccines
- Pregnancy and lactation
- Residual cellular DNA in vaccines
- Rotavirus vaccines
- Smallpox vaccines
- Thiomersal and vaccines
- Transmissible spongiform encephalopathies
- Typhoid vaccines
- Varicella Zoster virus
- Vaccinating adolescents and young adults
- Vaccine formulations
- Vaccines produced on yeast
- Vaccine Safety Information
- Yellow fever vaccines
- Vaccine safety indicator
- Oculorespiratory syndrome
- Mpox
- Communication
- Respiratory syncytial virus (RSV)
Contact us
Pharmacovigilance (PVG)
World Health Organization
20 avenue Appia
1211 Geneva 27
Switzerland
Email: gvsi@who.int